Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?

摘要

Objective The expense of new therapies for HCV infection may force health systems to prioritise the treatment of certain patient groups over others. Our objective was to forecast the population impact of possible prioritisation strategies for the resource-rich setting of Scotland.